Liver disease induced by radioembolization of liver tumors: description and possible risk factors
- PMID: 18260156
- DOI: 10.1002/cncr.23339
Liver disease induced by radioembolization of liver tumors: description and possible risk factors
Abstract
Background: To the authors' knowledge, liver damage after liver radioembolization with yttrium90-labeled microspheres has never been studied specifically.
Methods: Using a complete set of data recorded prospectively among all patients without previous chronic liver disease treated by radioembolization at the authors' institution from September 2003 to July 2006, patterns of liver damage were identified and possible risk factors were analyzed.
Results: In all, 20% of patients developed a distinct clinical picture that appeared 4 to 8 weeks after treatment and was characterized by jaundice and ascites. Veno-occlusive disease was the histologic hallmark observed in the most severe cases. This form of sinusoidal obstruction syndrome was not observed among patients who never received chemotherapy or in those in whom a single hepatic lobe was treated. Relevant to treatment planning, a possible risk factor was a higher treatment dose in relation to the targeted liver volume. A transjugular intrahepatic stent shunt improved liver function in 2 patients with impending liver failure, although 1 of them eventually died from it.
Conclusions: Radioembolization of liver tumors, particularly after antineoplastic chemotherapy, may result in an uncommon but potentially life-threatening form of hepatic sinusoidal obstruction syndrome that presents clinically with jaundice and ascites.
Similar articles
-
Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.J Vasc Interv Radiol. 2011 Oct;22(10):1373-9. doi: 10.1016/j.jvir.2011.06.006. Epub 2011 Jul 20. J Vasc Interv Radiol. 2011. PMID: 21764600
-
Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.J Vasc Interv Radiol. 2008 Aug;19(8):1187-95. doi: 10.1016/j.jvir.2008.05.013. Epub 2008 Jun 27. J Vasc Interv Radiol. 2008. PMID: 18656012
-
Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.J Vasc Interv Radiol. 2007 Nov;18(11):1375-82. doi: 10.1016/j.jvir.2007.07.016. J Vasc Interv Radiol. 2007. PMID: 18003987 Clinical Trial.
-
General selection criteria of patients for radioembolization of liver tumors: an international working group report.Am J Clin Oncol. 2011 Jun;34(3):337-41. doi: 10.1097/COC.0b013e3181ec61bb. Am J Clin Oncol. 2011. PMID: 20921882 Review.
-
Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors.Future Oncol. 2007 Feb;3(1):73-81. doi: 10.2217/14796694.3.1.73. Future Oncol. 2007. PMID: 17280504 Review.
Cited by
-
Safety and Efficacy of Selective Internal Radionuclide Therapy with 90Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization.Pharmaceuticals (Basel). 2024 Jan 11;17(1):101. doi: 10.3390/ph17010101. Pharmaceuticals (Basel). 2024. PMID: 38256934 Free PMC article.
-
Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.Diagnostics (Basel). 2023 Dec 12;13(24):3652. doi: 10.3390/diagnostics13243652. Diagnostics (Basel). 2023. PMID: 38132236 Free PMC article.
-
AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization.J Appl Clin Med Phys. 2024 Feb;25(2):e14157. doi: 10.1002/acm2.14157. Epub 2023 Oct 11. J Appl Clin Med Phys. 2024. PMID: 37820316 Free PMC article.
-
Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review.Clin Transl Oncol. 2024 Apr;26(4):851-863. doi: 10.1007/s12094-023-03299-y. Epub 2023 Sep 25. Clin Transl Oncol. 2024. PMID: 37747636 Free PMC article. Review.
-
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.Cancers (Basel). 2023 Aug 26;15(17):4274. doi: 10.3390/cancers15174274. Cancers (Basel). 2023. PMID: 37686549 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical